understanding and managing peripheral neuropathy

Download Understanding and Managing Peripheral Neuropathy

Post on 02-Jan-2017

215 views

Category:

Documents

1 download

Embed Size (px)

TRANSCRIPT

  • WINTER/SPRING 2010 BETA 27

    Peripheral neuropathy is the most

    common neurological disorder in peo-

    ple with HIV infection. It can be a ma-

    jor source of pain and discomfort and

    a limiting factor in antiretroviral treat-

    ment. Since the introduction of highly

    active antiretroviral therapy (HAART)

    in the mid-1990s, the overall incidence

    of neurological complications of HIV

    such as HIV-associated dementia and

    central nervous system opportunistic

    infectionshas decreased; however,

    rates of peripheral nervous system

    complications remain high.

    There are numerous current treatment options for peripheral neuropathy and many new candidates under investigation. Appropriate treatment can improve functioning and quality of life for individuals with this common condition.

    A Snapshot of the Nervous SystemThe nervous system enables humans to process and re-spond to external and internal information. It is comprised of two major components: the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS includes the brain and spinal cord, which are both enclosed in bone (the skull and the vertebrae) and sur-rounded by cerebrospinal fluid (CSF). The PNS consists of spinal nerves (originating from the spinal cord) and cranial nerves (originating from the brain), as well as ganglia, which are groups of nerve cells located outside of the CNS. Spinal nerves have a motor nerve root and sensory nerve root, which meet to form a single nerve. The PNS transmits information to the CNS through afferent nerves, which primarily pass along sensory infor-mation, and from the CNS through efferent nerves, which primarily deliver motor commands (for example, the com-mand to contract a muscle). There are more than 100 billion nerve cells in the PNS. Functionally, the PNS is organized into two divisions:

    Understanding and Managing

    Peripheral Neuropathy

    Anne Monroe, MD, MSPH

  • 28 BETA WINTER/SPRING 2010

    the somatic nervous system and the autonomic nervous system. The so-matic nervous system controls receipt of sensory signals and voluntary move-ments. The autonomic nervous system controls internal bodily functions that do not require conscious effort, such as breathing and the contraction of the heart muscle. Nerve cells, or neurons, have a large cell body and an axon that ex-tends from the cell body to send signals to other nerve cells. Branches called dendrites receive signals from other neurons. Some axons are surrounded by cells containing myelin, a soft, fatty material that forms a protective sheath. The myelin sheath serves as insulation so that signals can be transmitted more quickly through the neurons.

    Clinical Features of Peripheral NeuropathyPeripheral neuropathy is one of many neurological conditions that can affect people with HIV, and it is the most common peripheral nervous system complication associated with HIV disease and antiretroviral treatment. (For more on CNS manifestations, see HIV and the Brain, BETA, Summer/Fall 2009.) The type of peripheral neuropa-thy most often seen in HIV positive peoplemore specifically called distal symmetric polyneuropathy (DSPN)is characterized by pain and paresthesias (abnormal sensations such as numb-ness, tingling, pricking, burning, or creeping). Symptoms typically start in the toes and progress over a period of weeks to months, slowly moving upward to involve the lower limbs up to the knees. The upper extremities are rarely involved at early stages. As its name suggests, the condition typically affects both sides of the body. Other manifestations of DSPN include allodynia (a pain response to a normally non-painful stimulus like gentle touch), severe burning pain, or a pins and needles sensation. The pain associated with DSPN can be mild to severe and even debilitating,

    and may interfere with walking and other activities of daily living.

    Development of DSPNTwo types of DSPN are recognized in the context of HIV disease: DSPN re-lated to HIV infection itself and DSPN related to antiretroviral therapy. In some individuals, both HIV itself and antiretroviral drugs play a role. HIV-related and treatment-related DSPN are impossible to distinguish clinically; however, DSPN associated with use of the d-drugs or dideoxy-nucleosidesddI (didanosine; Videx), d4T (stavudine; Zerit), and ddC (zal-citabine; Hivid, withdrawn from the U.S. market in 2005)usually occurs within the first year of treatment. If an individual tolerates early exposure to these agents, it is unlikely that d-drug-related DSPN will develop with prolonged use. DSPN is the result of damage to axons or loss of their protective myelin sheaths (known as demyelination), but HIV does not directly infect nerve cells. Instead, HIV infection leads to immune activation and production of inflammatory chemicals called cyto-kines that cause axon damage. In ad-dition, the gp120 envelope protein of the virus causes neuron apoptosis (cell death). Slowly, axons degenerate and are lost, starting with the nerve cells farthest from the CNS. DPSN caused by antiretroviral drugs is thought to be due to impaired mitochondrial function. Mitochondria are structures within a cell that pro-duce energy and are involved in other crucial cell functions. Different nucleo-side/nucleotide reverse transcriptase inhibitors (NRTIs) are associated with varying degrees of mitochondrial toxic-ity, with ddC causing the most dam-age, followed by d4T, ddI, and AZT (zidovudine; Retrovir). The remaining drugs in this class3TC (lamivudine; Epivir), emtricitabine (Emtriva), abacavir (Ziagen), and tenofovir (Vi-read)are less likely to interfere with mitochondrial function. Other types of antiretroviral drugs,

    including non-nucleoside reverse tran-scriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, and entry inhibitors, are less likely to cause mitochondrial toxicity.

    Diagnosing DSPNDSPN is a clinical diagnosis, based on reports of symptoms, findings on physical exams, and ruling out other potential causes. If a patient reports symptoms such as pain, burning, numbness, or tingling in the feet, a neurological exam may help determine the cause of the symptoms. A complete neurological examina-tion includes a mental status exam (orientation to person, place, and time), assessment of cranial nerve function, motor function (strength in the hands and feet), sensory func-tion (sensation in both hands and both feet), neurovascular examination (including pulses in the feet), reflexes, and coordination and gait. Typical findings in people with DSPN include decreased sensation to pain and tem-perature in the feet. Diminished ankle reflexes may also be noted. Many clinical conditions in addi-tion to HIV can cause DSPN, including diabetes, alcoholism, thyroid disease, syphilis, hepatitis C, kidney disease, and vitamin B12 deficiency. A careful clinical history and laboratory testing are used to rule out these conditions. Use of neurotoxic drugs can also sug-gest a diagnosis of DSPN. If an individual has atypical symp-tomsfor example, an asymmetric distribution of numbness or pain, or weakness as the presenting symptom rather than sensory impairmentaddi-tional testing may be required to reach a diagnosis. Nerve conduction velocity (NCV) testing or electromyography (EMG) can be used to evaluate neurological symptoms. NCV checks the speed of signals transmitted through nerves using electrodes placed on the surface of the skin. NCV only detects damage to large nerves, so it may not detect DSPN, which predominantly affects small nerves.

    uNdERSTANdING ANd mANAGING PERIPhERAl NEuRoPAThy

  • WINTER/SPRING 2010 BETA 29

    EMG uses a thin needle electrode placed into muscle tissue to monitor electrical activity and detect whether the muscle has a normal ability to respond to electrical stimuli from nerves. In people with DSPN, EMG testing can occasionally show evidence of denervation (loss of nerve supply) in the distal (farther from the hips and shoulders) muscles of the limbs, such as those in the calves and forearms. EMG can also help distinguish DSPN from related neurological problems such as those associated with aging. Another type of testing frequently used in DSPN research, but less fre-quently in clinical care, is quantitative sensory testing, a non-invasive method used to assess the ability of nerves to re-spond to vibration and temperature. This test provides useful information about the extent of neuropathy and whether a patient is responding to treatment. Skin biopsy with analysis of epidermal nerve fiber density is also frequently used in DSPN research. Small skin samples are usually taken from the thigh, calf, and/or foot. Low nerve fiber density (

  • 30 BETA WINTER/SPRING 2010

    however, earlier initiation of HAARTeven a regimen including d4Tprovid-ed more protection against DSPN than withholding combination antiretroviral therapy. After six to twelve months of therapy, the incidence of DSPN reached a plateau. Further analysis of the HOPS data revealed an increase in DSPN from 1992 to 1995 following introduction of the d-drugs, then a decrease start-ing with the introduction of PI- and NNRTI-based HAART in 1996. A lower nadir CD4 count was associated with higher incidence of DSPN. In the HAART era, risk factors for peripheral neuropathy included age greater than 40 years, diabetes, nadir CD4 count less than 50 cells/mm3, and viral load greater than 10,000 copies/mL. Another HAART-era study by Catherine Cherry of Monash Uni-versity in Melbourne, Australia, and colleagues enrolled 147 HIV positive adults, 76 from Johns Hopkins Univer-sity in Baltimore, and 71 from Monash. The Melbourne group was enrolled first and subsequently the Baltimore group was matched according to rates of prior exposure to d4T and ddI. A

Recommended

View more >